All In Biotech

Drug Trial Radar · NCT07805551

A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer

A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HDM2017 Combination Therapy in Participants With Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Aug 2030

Study completion Aug 2032

Sponsor

Sponsor type
Industry
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, dose-escalation/dose-expansion, Phase Ib/II study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of HDM2017 combination therapy in participants with advanced CRC. The study is divided into two periods: dose escalation (Phase Ib) and dose expansion (Phase II). Phase Ib of this study is a dose-finding study of different HDM2017 combination therapies. The Phase II study will be conducted at a dose determined to be safe and potentially effective in Phase Ib.

Conditions

  • CRC, Colorectal Cancer

Interventions

  • HDM2017Drug

    Administered with continuing until protocol-specified criteria for treatment discontinuation are met

  • BevacizumabDrug

    administered with continuing until protocol-specified criteria for treatment discontinuation are met

  • OxaliplatinDrug

    administered with continuing until protocol-specified criteria for treatment discontinuation are met

  • FluorouracilDrug

    administered with continuing until protocol-specified criteria for treatment discontinuation are met

  • CapecitabineDrug

    administered with continuing until protocol-specified criteria for treatment discontinuation are met

  • LeucovorinDrug

    administered with dosing continuing until protocol-specified criteria for treatment discontinuation are met

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: 30 days after the last dose of IMP
  2. Recommended Phase 2 Dose (RP2D)Time frame: 30 days after the last dose of IMP
  3. Type, incidence and severity of Adverse EventsTime frame: 30 days after the last dose of IMP
  4. Objective Response Rate (ORR)Time frame: From date of first-dosing until the date of first documented progression or date of 30 days after the last dose of IMP, whichever came first, assessed up to about 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.